Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab with or without ipilimumab versus standard follow-up after surgery and adjuvant therapy in resectable head and neck squamous cell carcinoma
2016-004758-13Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Disease-free survival at 3 years. Started Sep 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-004758-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004758-13.